Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Top Cited Papers
- 22 March 2018
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 131 (12), 1275-1291
- https://doi.org/10.1182/blood-2017-09-801498
Abstract
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, post-diagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.This publication has 100 references indexed in Scilit:
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionBlood, 2013
- Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variationGenome Research, 2013
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid LeukemiaScience Translational Medicine, 2012
- Detection of ultra-rare mutations by next-generation sequencingProceedings of the National Academy of Sciences of the United States of America, 2012
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialThe Lancet Oncology, 2010
- Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1Cytometry Part B: Clinical Cytometry, 2008
- Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia‐associated immunophenotypesCytometry Part B: Clinical Cytometry, 2007
- Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioningBone Marrow Transplantation, 2003